Literature DB >> 16847588

At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis.

F Borgström1, O Johnell, J A Kanis, B Jönsson, C Rehnberg.   

Abstract

INTRODUCTION: Intervention thresholds (ITs), the 10-year hip fracture risk at which treatment can be considered to be cost-effective, have previously been estimated for Sweden and the UK.
OBJECTIVE: The aim of this study was to provide a Markov cohort model platform for a multinational estimation of thresholds at which intervention becomes cost-effective and to investigate and determine the main factors behind differences in these thresholds between countries. RESULTS AND DISCUSSION: Intervention thresholds were estimated for Australia, Germany, Japan, Sweden, Spain, the UK and USA using a societal perspective. The model was populated with as much relevant country-specific data as possible. Intervention was assumed to be given for 5 years and to decrease the risk of all osteoporotic fractures by 35%. The societal willingness to pay (WTP) for a quality-adjusted life-year (QALY) gained was set to the gross domestic product (GDP) per capita multiplied by two. In the base case analysis, the 10-year hip fracture probability at which intervention became cost-effective varied across ages and countries. For women starting therapy at an age of 70 years, the IT varied from a hip fracture probability of 5.6% in Japan to 14.7% in Spain. The main factors explaining differences in the IT between countries were the WTP for a QALY gained, fracture-related costs and intervention costs.
CONCLUSION: The ITs presented in this paper are appropriate for use in treatment guidelines that consider health economic aspects, and they can be used in combination with fracture risk prediction algorithms to improve the selection of patients who are suitable for osteoporotic intervention.

Entities:  

Mesh:

Year:  2006        PMID: 16847588     DOI: 10.1007/s00198-006-0107-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  58 in total

1.  Effect and offset of effect of treatments for hip fracture on health outcomes.

Authors:  B Jonsson; J Kanis; A Dawson; A Oden; O Johnell
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

Review 2.  Treatment of established osteoporosis: a systematic review and cost-utility analysis.

Authors:  J A Kanis; J E Brazier; M Stevenson; N W Calvert; M Lloyd Jones
Journal:  Health Technol Assess       Date:  2002       Impact factor: 4.014

3.  Accounting for future costs in medical cost-effectiveness analysis.

Authors:  D Meltzer
Journal:  J Health Econ       Date:  1997-02       Impact factor: 3.883

4.  Direct clinical and welfare costs of osteoporotic fractures in elderly men and women.

Authors:  A Randell; P N Sambrook; T V Nguyen; H Lapsley; G Jones; P J Kelly; J A Eisman
Journal:  Osteoporos Int       Date:  1995       Impact factor: 4.507

5.  The burden of osteoporotic fractures: a method for setting intervention thresholds.

Authors:  J A Kanis; A Oden; O Johnell; B Jonsson; C de Laet; A Dawson
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

6.  Age- and gender-specific rate of fractures in Australia: a population-based study.

Authors:  K M Sanders; E Seeman; A M Ugoni; J A Pasco; T J Martin; B Skoric; G C Nicholson; M A Kotowicz
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

7.  International variations in hip fracture probabilities: implications for risk assessment.

Authors:  John A Kanis; Olof Johnell; Chris De Laet; Bengt Jonsson; Anders Oden; Alan K Ogelsby
Journal:  J Bone Miner Res       Date:  2002-07       Impact factor: 6.741

8.  The components of excess mortality after hip fracture.

Authors:  J A Kanis; A Oden; O Johnell; C De Laet; B Jonsson; A K Oglesby
Journal:  Bone       Date:  2003-05       Impact factor: 4.398

9.  The apparent incidence of hip fracture in Europe: a study of national register sources.

Authors:  O Johnell; B Gullberg; E Allander; J A Kanis
Journal:  Osteoporos Int       Date:  1992-11       Impact factor: 4.507

10.  A family history of fracture and fracture risk: a meta-analysis.

Authors:  J A Kanis; H Johansson; A Oden; O Johnell; C De Laet; J A Eisman; E V McCloskey; D Mellstrom; L J Melton; H A P Pols; J Reeve; A J Silman; A Tenenhouse
Journal:  Bone       Date:  2004-11       Impact factor: 4.398

View more
  43 in total

1.  Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.

Authors:  F Borgström; O Ström; M Kleman; E McCloskey; H Johansson; A Odén; J A Kanis
Journal:  Osteoporos Int       Date:  2010-06-08       Impact factor: 4.507

Review 2.  The role of DXA bone density scans in the diagnosis and treatment of osteoporosis.

Authors:  Glen M Blake; Ignac Fogelman
Journal:  Postgrad Med J       Date:  2007-08       Impact factor: 2.401

3.  BMD, clinical risk factors and their combination for hip fracture prevention.

Authors:  H Johansson; J A Kanis; A Oden; O Johnell; E McCloskey
Journal:  Osteoporos Int       Date:  2009-03-17       Impact factor: 4.507

4.  The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E V McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-30       Impact factor: 4.507

5.  Added value of cost-utility analysis in simple diagnostic studies of accuracy: (18)F-fluoromethylcholine PET/CT in prostate cancer staging.

Authors:  Oke Gerke; Mads H Poulsen; Poul Flemming Høilund-Carlsen
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

Review 6.  Economic burden of osteoporosis-related hip fracture in Asia: a systematic review.

Authors:  N-A Mohd-Tahir; S-C Li
Journal:  Osteoporos Int       Date:  2017-03-17       Impact factor: 4.507

7.  Latitude, socioeconomic prosperity, mobile phones and hip fracture risk.

Authors:  O Johnell; F Borgstrom; B Jonsson; J Kanis
Journal:  Osteoporos Int       Date:  2006-11-01       Impact factor: 4.507

8.  The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-10       Impact factor: 4.507

Review 9.  A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.

Authors:  John A Kanis; Nicholas C Harvey; Cyrus Cooper; Helena Johansson; Anders Odén; Eugene V McCloskey
Journal:  Arch Osteoporos       Date:  2016-07-27       Impact factor: 2.617

Review 10.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; N Burlet; C Cooper; P D Delmas; J-Y Reginster; F Borgstrom; R Rizzoli
Journal:  Osteoporos Int       Date:  2008-02-12       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.